- Datum14.05.2025
- Uhrzeit15:00 - 16:00 Uhr
- Veranstalter
XTB
Jochen Schmidt
Moderator
Vaxart Inc. Aktie
Verkaufen
Kaufen
Vaxart Inc. Chart
Vaxart Inc. Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
2,59 %
Intraday
6,89 %
1 Woche
15,80 %
1 Monat
-37,25 %
Seit Jahresbeginn
-51,95 %
1 Jahr
-87,56 %
3 Jahre
-86,20 %
5 Jahre
Passender Service zu Vaxart Inc.
Webinar zu Vaxart Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)0,285-1,070
- Jahrestief / Hoch ($)0,285-0,980
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Vaxart Inc.
Keine Dividenden verfügbar
Termine von Vaxart Inc.
Keine aktuellen Termine
Beschreibung
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
